Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report by Product (Instruments, Reagents), By Technology (PCR), By Application, By End Use, By Region, And Segment Forecasts, 2024 - 2030

Report Overview

The global infectious disease molecular diagnostics market size was valued at USD 52.0 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2030. The market surge is attributable to the increasing prevalence of infectious diseases worldwide. Diseases such as HIV/AIDS, hepatitis, tuberculosis, and respiratory infections continue to pose significant public health challenges, necessitating advanced diagnostic solutions. In addition, the aging global population contributed to market growth, as older individuals are more susceptible to infections and require frequent diagnostic testing.

The technological advancements in molecular diagnostics have revolutionized the field, making tests more accurate, faster, and accessible. Techniques such as Polymerase Chain Reaction (PCR), nucleic acid amplification, and next-generation sequencing have enhanced the ability to detect pathogens with high precision. These innovations have improved diagnostic accuracy and reduced the time required to obtain results, crucial for timely treatment and containment of infectious diseases.

Government initiatives and public health campaigns aimed at controlling the spread of infectious diseases considerably propelled market growth. Governments and health organizations worldwide have heavily invested in screening programs, awareness campaigns, and early detection initiatives. These efforts emphasize the importance of early diagnosis and treatment, driving the adoption of molecular diagnostic technologies. In addition, regulatory support and funding for research and development have fostered significant innovation in the field.

In addition, healthcare infrastructure improvements in emerging economies have expanded access to molecular diagnostics. Countries in Asia Pacific, Africa, and Latin America have invested heavily in healthcare facilities and diagnostic laboratories, increasing the availability of advanced diagnostic tests. Patients have increasingly favored molecular diagnostics that enable the identification of specific genetic markers and pathogens, allowing for tailored treatment plans. This personalized approach enhances treatment efficacy and reduces the risk of adverse effects.

Product Insights

Reagents dominated the market with a 57.1% share in 2023 owing to their high-volume usage for diagnosing infectious diseases. Reagents are essential components in molecular diagnostic tests, including PCR, nucleic acid amplification, and sequencing, which are widely used for detecting pathogens with high accuracy. The pandemic has significantly boosted the demand for reagents, as extensive testing programs were implemented globally to screen for SARS-CoV-2 infections. This surge in demand has led to increased production and commercialization of novel reagents, further driving market growth. In addition, technological innovations in reagent formulations have improved the efficiency and reliability of diagnostic tests. These advancements have facilitated the development of point-of-care (PoC) testing, which relies heavily on high-quality reagents for rapid and accurate results.

Services are expected to emerge at the fastest CAGR over the forecast period with the increasing demand for specialized diagnostic services that offer comprehensive testing solutions for various infectious diseases. These services include laboratory testing, data analysis, and interpretation, essential for accurate diagnosis and effective treatment planning. Moreover, innovations such as Next-Generation Sequencing (NGS), digital PCR, and automated platforms have enhanced the capabilities of diagnostic services, enabling more precise and efficient detection of pathogens. These advancements have made it possible to offer a wider range of diagnostic tests, including those for emerging and rare infectious diseases.

Technology Insights

Polymerase Chain Reaction (PCR) technology secured the dominant market share in 2023 owing to its widespread application in detecting a broad range of infectious diseases, including COVID-19, HIV, hepatitis, and tuberculosis. PCR’s ability to amplify small amounts of DNA or RNA to detectable levels makes it an invaluable tool for accurate and early diagnosis. Furthermore, technological advancements such as real-time PCR (qPCR) and digital PCR (dPCR) improved the sensitivity and specificity of tests, enabling the detection of low-abundance pathogens and genetic mutations.

In Situ Hybridization (ISH) technology is expected to grow at a CAGR of 7.3% over the forecast period. ISH technology enables the precise localization of specific nucleic acid sequences within cells and tissues, making it invaluable for diagnosing diseases with high accuracy. Innovations such as fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) have improved the sensitivity and specificity of diagnostic tests. These advancements allow for the visualization and quantification of viral loads, gene expression, and chromosomal abnormalities, which are crucial for accurate diagnosis and treatment planning. In addition, governments and health organizations have heavily invested in advanced diagnostic tools to enhance their capacity for early detection and management of infectious diseases.

Application Insights

Tuberculosis (TB) accounted for a 1.5% market share in 2023 owing to its increasing incidence. According to the World Health Organization (WHO), TB continues to be one of the top infectious disease killers globally. The resurgence of TB cases, particularly in regions with high HIV prevalence and in areas with limited healthcare infrastructure, underscores the need for advanced diagnostic solutions. Moreover, healthcare providers and patients have increasingly favored real-time PCR, nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS), which have improved the sensitivity and specificity of TB diagnostics. These technologies enable the rapid identification of Mycobacterium tuberculosis, the bacterium responsible for TB, and its drug-resistant strains, facilitating timely and appropriate treatment.

Human Papillomavirus (HPV) diagnostics are projected to boost as the fastest growing segment over the forecast period. The market growth can be credited to the high prevalence of HPV infections worldwide, which are a leading cause of cervical cancer and other anogenital cancers. The increasing incidence of HPV-related cancers has heightened the demand for effective diagnostic tools to enable early detection and intervention. Moreover, the implementation of widespread HPV vaccination programs has influenced the market, driving the need for robust diagnostic tools to monitor vaccine efficacy and identify breakthrough infections. This dual approach of prevention and monitoring is essential for comprehensive HPV management.  

End Use Insights

Diagnostic laboratories registered the dominant market share in 2023 due to the increasing prevalence of infectious diseases such as HIV, hepatitis, hepatitis, tuberculosis, and respiratory infections. These diseases require accurate and timely diagnosis. Diagnostic laboratories are well-equipped to cater to patients with advanced infrastructure and expertise. In addition, the shift toward personalized medicine influenced the demand for diagnostic laboratory services. Molecular diagnostics enable the identification of specific genetic markers and pathogens, allowing for tailored treatment plans. This personalized approach enhances treatment efficacy and reduces the risk of adverse effects.

Hospitals are expected to emerge at a CAGR of 31.5% during the forecast period. The market witnessed an increasing rate of hospitalizations due to infectious diseases such as COVID-19, influenza, HIV, and tuberculosis. Hospitals require rapid and accurate diagnostic tools to manage and treat these infections effectively, making molecular diagnostics indispensable in hospital settings. In addition, the pandemic led to a surge in demand for molecular diagnostic tests, prompting hospitals to invest in advanced diagnostic technologies to manage the high volume of testing required.

Regional Insights

The North America infectious disease molecular diagnostics market accounted for 34.4% of the market share in 2023 owing to the high prevalence of infectious diseases such as COVID-19, influenza, HIV, and hepatitis. The ongoing need for accurate and timely diagnosis of these diseases has significantly boosted the demand for molecular diagnostic tools. In addition, the rising demand for point-of-care (PoC) testing has influenced the market. This testing allows for rapid diagnosis at the patient’s bedside or in community settings, which is essential for timely treatment and containment of infectious diseases.

U.S. Infectious Disease Molecular Diagnostics Market Trends

The infectious disease molecular diagnostics market in U.S. is expected to grow considerably over the forecast period. The surge can be credited to technological innovations such as real-time PCR, NGS, and digital PCR that have enhanced the accuracy, speed, and efficiency of diagnostic tests. These advancements enable healthcare providers to identify pathogens and determine appropriate treatment plans, which is critical for patient outcomes and infection control.

Europe Infectious Disease Molecular Diagnostics Market Trends

The Europe infectious disease molecular diagnostics market registered a significant market share in 2023. The market was significantly stimulated by the significant investments in diagnostic infrastructure and technology. Moreover, regional governments have increasingly aimed at strengthening healthcare infrastructure. They have significantly invested in diagnostic technologies to enhance their capacity for early detection and management of infectious diseases and improve public health outcomes.

Asia Pacific Infectious Disease Molecular Diagnostics Market Trends

The infectious disease molecular diagnostics market in Asia Pacific is expected to grow at the fastest CAGR of 6.9% over the forecast period. The rising prevalence of infectious diseases including COVID-19, tuberculosis, HIV, and hepatitis is one of the key driving factors. The high burden of these diseases in the region necessitates advanced diagnostic solutions for accurate and timely detection, which is crucial for effective disease management and control. In addition, the rising geriatric population in Asia Pacific has influenced the demand for molecular diagnostics. Furthermore, the increasing number of biotechnology and biopharmaceutical companies in the region has contributed to market growth by fostering innovation and expanding the availability of advanced diagnostic tools.

Key Companies & Market Share Insights

The global infectious disease molecular diagnostics market is highly competitive. Key market participants including Danaher Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, and others have focused on developing products that excel in speed, accuracy, specialty, precision, and other parameters. They have increasingly focused on new product development with R&D activities and acquisitions and mergers to gain a competitive edge.

• Danaher Corporation is a global conglomerate that operates in various sectors, including life sciences, diagnostics, and environmental and applied solutions. The company is known for its innovative approach, adopting Kaizen principles of continuous improvement and efficiency early on. The company designs, manufactures, and markets a wide range of medical, industrial, and commercial products and services.

• Bio-Rad Laboratories, Inc. is an American company specializing in the development and manufacturing of products for the life science research and clinical diagnostics markets. The company offers a wide array of instruments, software, consumables, reagents, and content for various scientific applications, including cell biology, gene expression, protein purification, and drug discovery.

Recent Developments

• In January 2024, bioMérieux announced the acquisition of LUMED, a software company known for developing a clinical decision support system. This system aids hospitals in optimizing antimicrobial prescriptions and monitoring healthcare-associated infections.

• In November 2023, Roche launched the LightCycler PRO System, which enhances usability and performance, effectively linking in-vitro diagnostics and translational research. This system expands the company’s molecular testing portfolio.
  
  

Infectious Disease Molecular Diagnostics Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global infectious disease molecular diagnostics market report based on product, technology, application, end use, and region. 

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments

  • Reagents

  • Services

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Polymerase Chain Reaction (PCR)

    • Multiplex PCR

      • Instruments

      • Reagents

      • Others

    • Other PCR

  • In Situ Hybridization

    • Instruments

    • Reagents

    • Services

  • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Instruments

    • Reagents

    • Services

  • Chips and Microarrays

    • Instruments

    • Reagents

    • Services

  • Mass Spectrometry

    • Instruments

    • Reagents

    • Services

  • Transcription Mediated Amplification

    • Instruments

    • Reagents

    • Services

  • Others

    • Instruments

    • Reagents

    • Services

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Respiratory Diseases

  • Tuberculosis

  • Meningitis

  • Gastrointestinal Tract Infections

  • HPV

  • Sexually Transmitted Infections

  • Sepsis

  • Drug Resistance Diseases

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Clinics

  • Diagnostics Laboratories

  • Research Institutes

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait